InnoCare Pharma Limited (HKG:9969)
14.66
+0.39 (2.73%)
Aug 20, 2026, 4:09 PM HKT
InnoCare Pharma Revenue
InnoCare Pharma had revenue of 528.63M CNY in the quarter ending March 31, 2026, with 38.65% growth. This brings the company's revenue in the last twelve months to 2.52B, up 105.92% year-over-year. In the year 2025, InnoCare Pharma had annual revenue of 2.37B with 135.27% growth.
Revenue (ttm)
2.52B CNY
Revenue Growth
+105.92%
P/S Ratio
10.78
Revenue / Employee
2.14M CNY
Employees
1,176
Market Cap
30.91B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.37B | 1.37B | 135.27% |
| Dec 31, 2024 | 1.01B | 270.91M | 36.68% |
| Dec 31, 2023 | 738.54M | 113.13M | 18.09% |
| Dec 31, 2022 | 625.40M | -417.63M | -40.04% |
| Dec 31, 2021 | 1.04B | 1.04B | 76,368.70% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| 3SBio | 19.69B |
| Shanghai Henlius Biotech | 7.42B |
| Genscript Biotech | 6.63B |
| RemeGen | 3.84B |
| Zai Lab | 3.53B |
| Shanghai Junshi Biosciences | 3.10B |
| Duality Biotherapeutics | 2.06B |
| Biocytogen Pharmaceuticals (Beijing) | 1.78B |
InnoCare Pharma News
- 24 days ago - China's Innocare's psoriasis drug meets main goal in late-stage trial - Reuters
- 5 weeks ago - InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL - GlobeNewsWire
- 6 weeks ago - InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China - GlobeNewsWire
- 2 months ago - Phase IIb Study Results of InnoCare's Orelabrutinib in Patients with SLE Presented at 2026 EULAR - GlobeNewsWire
- 2 months ago - ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released - GlobeNewsWire
- 3 months ago - InnoCare Pharma upgraded to Overweight from Equal Weight at Morgan Stanley - TheFly
- 3 months ago - InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China - GlobeNewsWire
- 3 months ago - InnoCare Announces Approval of Orelabrutinib in Australia - GlobeNewsWire